- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03277911
Thyroid Dysfunction and Dyslipidemia in Patients With Chronic Kidney Diseases
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Chronic kidney disease[CKD] is becoming a serious health problem.The number of people with impaired renal function is rapidly rising, especially in industrialized countries. It is increasing rapidly worldwide at an annual growth rate of 8%. Chronic kidney disease [CKD] is defined as kidney disease that has been present for months to years. Chronic kidney disease [CKD] is a complex disease impacting more than twenty million individuals. Progression of CKD is associated with a number of serious complications, including increased incidence of cardiovascular disease, hyperlipidemia, anemia and metabolic bone disease .CKD patients should be assessed for the presence of these complications and receive optimal treatment to reduce their morbidity and mortality .
CKD affects thyroid function in many ways, including low thyroid circulating hormone levels, altered peripheral hormone metabolism, insufficient binding to carrier proteins, reduced tissue thyroid hormone content and altered iodine storage in the thyroid gland.Thus,inCKD,thyroid hormone metabolism is impaired. . Hypothyroidism in patients with renal failure causes many metabolic and clinical problems, and both these diseases can mutually exacerbate their disturbances.. Chronic kidney disease has been known to affect thyroid hormones metabolism .Low serum level of T3 and T4 are most remarkable laboratorial finding. A high incidence of goiter and nodules on thyroid ultrasonography has been reported in patients with end stage renal failure[ESRF]. CKD is often associated with dyslipidemia. Several factors contribute to these changes. Patient with CKD have a reduction in the activity of lipoprotein lipase and hepatic triglyceride lipase. This interferes with uptake of triglyceride rich Apo lipoprotein B containing lipoprotein by the liver and in peripheral tissue, yielding increased circulation of these atherogenic lipoproteins. Early diagnosis of thyroid and lipid disorders by regular screening, and treatment of such disorders in CKD patients may be highly beneficial to slow progression of CKD.
Tipo de estudio
Inscripción (Anticipado)
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
The study will be conducted on 80 patients with chronic kidney disease at Assuit University hospital to investigate thyroid function and lipid profile in patients with CKD of stages (1-5) and 20 subjects as a normal control. A total of newly diagnosed and known CKD cases of stage 1-5 will be included in the study.
Sample Size Calculation:
- Group I: Controls-20 age and sex matched normal individuals.
- Group II: Cases -40 patients with stage 1-3.
- Group III: Cases -40 patients with stage 4 and 5
Descripción
Inclusion criteria:
- Patients with CKD stage (1-5).
- Not known thyroid disorders.
- Not in lipid lowering agents.
Exclusion Criteria:
- Patients with known thyroid disorders, on medication affecting thyroid function and lipid lowering agents are excluded from the study.
- CKD patients who were or underwent previous dialysis.
- Nephrotic syndrome.
- Obesity.
- Patients on estrogens, corticosteroids, antithyroid drugs, dietary supplements.
- Pregnant woman
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
The study will be conducted to investigate thyroid function in patients with chronic kidney disease
Periodo de tiempo: one year
|
serum urea, creatinine, , triiodothyronine [T3], free thyroxin [T4], thyroid stimulating hormones [TSH]
|
one year
|
The study will be conducted to investigate lipid profile in patients with chronic kidney disease
Periodo de tiempo: one year
|
serum urea, creatinine,high density lipoprotein [HDL] cholesterol, low density cholesterol, total cholesterol, triglyceride
|
one year
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Anticipado)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- Clincal Pathology
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre ERC
-
FibroGenAstraZeneca; Astellas Pharma Europe B.V.TerminadoAnemia CKD en pacientes estables en diálisisEstados Unidos, Puerto Rico
-
Affiliated Hospital of Nantong UniversityTerminadoComplicación de hemodiálisis | Trastorno de la articulación del hombro | CKD-MBDPorcelana
-
Medical University of ViennaTerminadoHiperparatiroidismo secundario | CKD-MBD - Enfermedad renal crónica Trastorno mineral y óseo | Reemplazo de RiñónAustria
-
Ospedale San RaffaeleReclutamientoHipertensión | LRA | ERC | Malignidad hematológica | Ckd-Mbd | ADPKD | Complicaciones del trasplante de médula ósea | ERC (enfermedad renal crónica) Etapa 5DItalia
-
Great Ormond Street Hospital for Children NHS Foundation...ReclutamientoEnfermedades Renales Crónicas | Hiperfosfatemia | Enfermedad renal crónica: trastorno mineral y óseo | Enfermedad renal pediátrica | CKD-MBDReino Unido
-
Thomas Nickolas, MD MSNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Indiana...ReclutamientoEnfermedades Renales Crónicas | Hiperparatiroidismo secundario | Osteodistrofia renal | Trastorno de la tasa de recambio óseo | CKD-MBDEstados Unidos